Discover our unique inAAVate™ platform

Your AAV development partner, from construct design through GMP manufacturing

We offer end-to-end AAV development and manufacturing capabilities, from plasmid design and optimisation, to pre-clinical development, through clinical and commercial GMP manufacturing. These capabilities are supported by robust quality control systems, advanced analytical methods, and in-depth knowledge of global regulatory requirements.

View our fact sheets

AAV Manufacturing

View factsheet

Dual Plasmid

View our factsheet

Our Services

We provide a flexible service offering designed to support you wherever you are in your development journey – whether you are in early phase or ready for commercial GMP manufacturing.

Construct & Plasmid Design
Analytical Method Development
Process Development
GMP Cell Banking
GMP Manufacturing
QA Release
Stability Studies
Regulatory Support

Benefits of Using Our Proven Platform

The inAAVate™ platform can provide:

Faster time to GMP with a proven scalable approach

Scalability from 2L up to 2,000L

 

Improved drug product stability with patented formulation

Higher titre and yield of drug substance with over 90% full vector which ensures a highly potent product

Reduced use of raw materials, such as plasmids, needed for manufacturing with our Dual-Plasmid transfection system

Proven formulation for over 10 AAV serotypes, eliminating the need for a tailor-made formulation

Large suite of in-house analytical methods for an accelerated GMP batch release

What makes the inAAVate™ platform unique?

+50+

50+

GMP batches successfully released in the past 2 years

Track record

  • >1E15vg/L bioreactor titer demonstrated across >10serotypes
  • Multiple GOIs Validated commercial platform

+1E17 vg

1E17 vg

of drug substance in 500ml

Performance

  • Recognised leading platform by multiple emerging biotechs and pharma companies

+10-fold Titre

10-fold Titre

Improvement achieved with OXB technologies

Innovation

  • Several peer reviewed journal papers

+9 months

9 months

Fastest timeline achieved from client onboarding to release CGMP batch

Process Improvements

  • Streamlined processes and validation of new equipment and techniques leads to faster and faster timelines

+40+

40+

Analytical methods developed for full vector characterisation, quality control, and stability testing

In-House testing

  • 90% of our methods are performed in-house, reducing risk and turn-around time

What we do

We know the challenges for AAV manufacturing, and we are ready.

Challenge: Low Performance. Solution: 3-fold AAV vector titre improvement with OXB technologies

Challenge: Maintaining High Quality. Solution: Improved F/E ratio with AAV Dual-Plasmid system & unique AEX chromatography step

Challenge: Speed Lengthy Analytical Development. Solution: Established platforms assays with >90% of testing performed in-house

Challenge: Scaling-Up. Solution: Scalability proven up to 2,000L and >90% AAV full vector achieved at all scales

Challenge: Regulatory Burden. Solution: Experience with IND submissions

See our other services

Services Overview

As a viral vector specialist with over 25 years experience in the cell and gene therapy industry, we have a thorough understanding 
of the challenges you face.

Manufacturing

OXB has the technical and regulatory expertise to help you deliver the life-changing medicines of tomorrow.

LentiVector® platform

The OXB LentiVector® platform has already helped thousands of patients received innovate and life-changing ex-vivo and in vivo treatments